Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584384 | 0.89 | KDM4E (0.51) | KDM4ERECQLSMN1; SMN2HTTGAA | |
| SCHEMBL29452250 | 0.82 | KDM4E (0.45) | KDM4ERECQLSMN1; SMN2HTTGAA | |
| SCHEMBL30120759 | 0.81 | KDM4E (0.63) | KDM4ERECQLSMN1; SMN2HTTMAPT | |
| SCHEMBL6930795 | 0.81 | KDM4E (0.56) | KDM4ERECQLSMN1; SMN2HTTMAPT | |
| SCHEMBL6930954 | 0.81 | KDM4E (0.63) | KDM4ERECQLSMN1; SMN2HTTMAPT | |
| SCHEMBL30120616 | 0.81 | KDM4E (0.56) | KDM4ERECQLSMN1; SMN2HTTMAPT | |
| SCHEMBL2722306 | 0.80 | KDM4E (0.67) | KDM4ERECQLGAAMAPTALDH1A1 | |
| SCHEMBL29900596 | 0.80 | KDM4E (0.67) | KDM4ERECQLGAAMAPTALDH1A1 | |
| SCHEMBL7092983 | 0.77 | KDM4E (0.53) | KDM4ERECQLGAAMAPTALDH1A1 | |
| SCHEMBL8529995 | 0.77 | KDM4E (0.66) | KDM4ESMN1; SMN2GAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | KDM4E 3566/4885RECQL 212/4885SMN1; SMN2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.